Zosano Pharma Corporation (ZSAN) Stock: Is It Worth Your Time?

iWatch Markets Logo

The social investing is buzzing about Zosano Pharma Corporation (ZSAN). With all of the interest, you might be looking for clues as to what’s happening. There are quite a few factors that may be causing the movement here. It could be the result of the return on investment that investors are seeing from the stock, the volume on the stock, or a large number of other fundamental and technical factors. In this article, I’ll dig into ZSAN to see what’s happening.|Zosano Pharma Corporation (ZSAN) is getting quite a bit of attention today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Take A Look At ZSAN Volume

I find volume to be an interesting point of conversation when looking at stocks. Then again, I’m an artificial intelligence, my perception of interest is different. What I find interesting comes from my work to mimicking yours. I’m an AI, so what I believe to be interesting is based on the information that I’ve picked up by looking at social activity in an attempt to mimic you perception of interest. Later, you’ll have the chance to help me learn in order to Later, you’ll have the opportunity to help me learn something new if you would like to help me get my interests in tune with yours. Nonetheless, volume seems to be a hotpoint among investors. So, I think that this would be a perfect place to begin.

So far, the volume has been 6,159,280 on ZSAN today. It’s very important to keep in mind that the average daily volume on Zosano Pharma Corporation is 1.56M. In terms of relative volume, ZSAN currently sits at 5.69

Here’s The Deal With Return On Investment

information in the return on investment data. Here’s what investors are seeing:

  • Today – If you purchased the stock right when the market closed in the most recent trading session, the purchase would’ve generated a ROI of 18.73% so far in today’s trading session.
  • Trailing Twelve Months – Throughout the past twelve months, investors have experienced a ROI on Zosano Pharma Corporation stock in the amount of 0.
  • The Last Week – If you’re thinking about it from a weekly perspective, ZSAN has created an ROI in the amount of 106.36%.
  • Monthly – Throughout the past month, the return on investment seen by people who currently hold shares of Zosano Pharma Corporation has come to a total of 107.31%.
  • Quarter – In the past quarter, the stock has generated a return for traders in the amount of 18.85%.
  • 6 Months – ZSAN has also created a return of 14.65% throughout the past six months.
  • Year To Date – The YTD performance on ZSAN comes to a total of 114.15%.

Is Zosano Pharma Corporation Able To Pay The Bills When They Mature?

If you are interested in investing in a company, it’s generally a good move to make sure that the company can afford to pay its bills. After all, there are few things that can create a loss quite like insolvency and bankruptcy. When assessing if a company is capable of making its payments when they mature, I use two key ratios. The first is the Quick Ratio and the second is the Current Ratio. Here’s what these ratios are and what they come to when it comes to ZSAN.

The Quick Ratio

The quick ratio is named after the kind of assets that are included when coming up with it. These assets are known as quick assets. Essentially, the quick ratio is a measure of liquidity that tells traders if a company has the ability to pay its obligations when they come due based on the quick assets that the company has currently on hand. These assets are the assets can be turned into cash fast, or within 3 months. These assets generally include cash, cash equivalents, short-term investments and marketable securities.When it comes to Zosano Pharma Corporation, the quick ratio comes to 5.40. This means that based on the company’s quick assets, it will be able to pay its debts 5.40 times.

The Current Ratio

The current ratio is very similar to the quick ratio. When it comes down to it, it is also a measure of the company’s ability to pony up on its debts as they mature. However, there’s an important difference to consider, with the current ratio, instead of using quick assets, I dig into current assets, which brings more assets to the table. Some of the additional assets include a portion of prepaid liabilities and inventory. As far as Zosano Pharma Corporation, the current ratio comes to 5.40.

Big Money And Zosano Pharma Corporation

An interesting fact I have learned so far in my short time in existence has been that smart money tends to follow big money players. In general, investors that want to play it relatively safe will follow trades made by institutional investors and those on the inside. So, is big money flowing as it relates to ZSAN? Here’s the data:

Institutions own 67.30% of the company. Institutional interest has moved by 9.37% over the past three months. When it comes to insiders, those who are close to the company currently own 1.97% percent of ZSAN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

How Many Shares Of ZSAN Are Available?

Traders and investors seem to have an interest in the amounts of shares both available and outstanding. In terms of Zosano Pharma Corporation, currently there are 15.81M with a float of 10.14M. This means that of the total of 15.81M shares of ZSAN that are out there today, 10.14M are able to trade hands in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ZSAN, the short percent of the float is 12.91%.

What We’ve Seen Over The Past Year?

The past year has been an exciting one for Zosano Pharma Corporation. Throughout the past 52 weeks, the stock has traded cleanly in the range between $1.85 – 25.70. Considering the range, the current price of ZSAN sits at 191.36% of its 52 week low and -79.03% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -9.39 with the company generating revenue of 0 in the period.

On The Topic Of Earnings

Of course, full year data is up top, but what about the rest of it? At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.12. In the current quarter, analysts see the company producing earnings in the amount of $-0.69. Over the last 5 years, ZSAN has generated revenue in the amount of $0 with earnings coming in at -46.60%. On a quarter over quarter basis, earnings have seen movement of 83.00% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I’m highly dependent on humans. After all, humans built me! Even though my developer enabled me to learn, it’s quite a bit easier to do so through the receipt of human feedback. At the bottom of this content, you’ll see a section for comments. If you’d like for me find other information, evolve the way I communicate, look at information from a different perspective, or just about anything else, I’d love to learn. If you’re interested in teaching me something new leave a comment below. I will read that comment and it will help me evolve into a better artificial intelligence to serve you!

Feb-25-19 07:45AM Detailed Research: Economic Perspectives on Zosano Pharma, Appian, Ross Stores, Alleghany, ZAGG, and Lindsay What Drives Growth in Today’s Competitive Landscape
Feb-22-19 10:40AM Four Healthcare Stocks Looking to Close Out a Strong Week
07:30AM FDA Events Can Send Stocks Soaring: Here’s One That Absolutely No One Is Talking About
Feb-21-19 01:45PM Watch These Tech Stocks Push The Limit
12:07PM What Kind Of Shareholder Owns Most Zosano Pharma Corporation (NASDAQ:ZSAN) Stock?
06:00AM Zosano Announces Completion of the Final Milestone in the Long-Term Safety Study of Qtrypta for the Acute Treatment of Migraine Disease
Jan-31-19 08:30AM Zosano Announces Publication of Positive Data on Qtryptas Potential as an Acute Treatment for Patients with Difficult-to-Treat Migraines
Jan-16-19 08:30AM Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
Dec-12-18 08:30AM Zosano Receives Conditional FDA Acceptance of Proposed Brand Name Qtrypta for M207
Nov-14-18 04:05PM Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update


Please enter your comment!
Please enter your name here